XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone510-204-7200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.30 million
Profitability
Miscellaneous
Employees11
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable
XOMA (NASDAQ:XOMA) Frequently Asked Questions
What is XOMA's stock symbol?
XOMA trades on the NASDAQ under the ticker symbol "XOMA."
How were XOMA's earnings last quarter?
XOMA Corp (NASDAQ:XOMA) issued its earnings results on Tuesday, August, 6th. The biotechnology company reported ($0.47) EPS for the quarter, beating the Zacks' consensus estimate of ($0.54) by $0.07. The biotechnology company earned $0.96 million during the quarter, compared to analysts' expectations of $0.63 million. XOMA had a negative net margin of 72.20% and a negative return on equity of 51.91%. View XOMA's Earnings History.
When is XOMA's next earnings date?
What price target have analysts set for XOMA?
3 equities research analysts have issued 1-year price objectives for XOMA's shares. Their forecasts range from $25.00 to $30.00. On average, they expect XOMA's share price to reach $27.50 in the next year. This suggests a possible upside of 49.1% from the stock's current price. View Analyst Price Targets for XOMA.
What is the consensus analysts' recommendation for XOMA?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for XOMA.
What are Wall Street analysts saying about XOMA stock?
Here are some recent quotes from research analysts about XOMA stock:
- 1. HC Wainwright analysts commented, "We project U.S. peak sales of $325M in 2026 for DSUVIA. For Zalviso, we project product launch in 1H20 (85% POS) with peak sales in 2027 of about $185M. We apply a 12.5% discount rate to both products." (4/12/2019)
- 2. According to Zacks Investment Research, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. " (3/9/2019)
Has XOMA been receiving favorable news coverage?
News stories about XOMA stock have been trending somewhat negative on Thursday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. XOMA earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for XOMA.
Are investors shorting XOMA?
XOMA saw a decrease in short interest in the month of September. As of September 30th, there was short interest totalling 474,300 shares, a decrease of 7.7% from the August 30th total of 513,600 shares. Based on an average daily volume of 69,800 shares, the days-to-cover ratio is presently 6.8 days. Approximately 6.0% of the company's stock are sold short. View XOMA's Current Options Chain.
Who are some of XOMA's key competitors?
Some companies that are related to XOMA include Axsome Therapeutics (AXSM), ZIOPHARM Oncology (ZIOP), Revance Therapeutics (RVNC), Homology Medicines (FIXX), NextCure (NXTC), Advanz Pharma (CXRXF), DiaMedica Therapeutics (DMCAF), MacroGenics (MGNX), Catalyst Pharmaceuticals (CPRX), Arvinas (ARVN), Flexion Therapeutics (FLXN), Akero Therapeutics (AKRO), IGM Biosciences (IGMS), OrganiGram (OGI) and INDIVIOR PLC/S (INVVY).
What other stocks do shareholders of XOMA own?
Who are XOMA's key executives?
XOMA's management team includes the folowing people:
- Mr. James R. Neal, CEO & Director (Age 63)
- Mr. Thomas M. Burns, Sr. VP of Fin. & CFO (Age 45)
- Mr. Danny J. Hart Jr., VP & Gen. Counsel (Age 43)
- Dr. Deepshikha Datta, Chief Bus. Officer
How do I buy shares of XOMA?
Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is XOMA's stock price today?
One share of XOMA stock can currently be purchased for approximately $18.44.
How big of a company is XOMA?
XOMA has a market capitalization of $160.94 million and generates $5.30 million in revenue each year. The biotechnology company earns $-13,340,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. XOMA employs 11 workers across the globe.View Additional Information About XOMA.
What is XOMA's official website?
How can I contact XOMA?
XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-204-7200 or via email at [email protected]
MarketBeat Community Rating for XOMA (NASDAQ XOMA)
MarketBeat's community ratings are surveys of what our community members think about XOMA and other stocks. Vote "Outperform" if you believe XOMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XOMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
